Literature DB >> 22584902

Bortezomib and bilateral herpes zoster.

Nicola di Meo1, Serena Bergamo, Adina Dondas, Giusto Trevisan.   

Abstract

Bortezomib is a proteasome inhibitor that has proven to be a very effective treatment for multiple myeloma. There is considerable debate about the potential for reactivation of the varicella zoster virus (VZV) in patients with multiple myeloma during treatment with bortezomib. This report describes the case of a 70-year-old patient with multiple myeloma that developed bilateral herpes zoster shortly after being treated with bortezomib. Furthermore, it emphasizes the importance of using an antiviral prophylaxis with acyclovir in these patients treated with bortezomib.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22584902

Source DB:  PubMed          Journal:  Acta Dermatovenerol Alp Pannonica Adriat        ISSN: 1318-4458


  2 in total

1.  Herpes Zoster Duplex Bilateralis After Trauma Induced Emotional Dysregulation: A Case Report and Literature Review.

Authors:  Tianhang Yu; Jikai Song; Xin Chen; Jin Li; Shuang Yang; Jie Yang
Journal:  Infect Drug Resist       Date:  2022-05-24       Impact factor: 4.177

2.  Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.

Authors:  Ji Young Yoo; Brian S Hurwitz; Chelsea Bolyard; Jun-Ge Yu; Jianying Zhang; Karuppaiyah Selvendiran; Kellie S Rath; Shun He; Zachary Bailey; David Eaves; Timothy P Cripe; Deborah S Parris; Michael A Caligiuri; Jianhua Yu; Matthew Old; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2014-05-09       Impact factor: 12.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.